1st Optimal Company Overview & Business Model: An Independent Clinical Assessment

What Is 1st Optimal and How Does Its Business Model Work?

1st Optimal is a direct-to-patient telehealth company that operates on a cash concierge model, meaning patients pay out-of-pocket for physician consultations, lab panels, and prescription medications. No insurance billing occurs. The company positions itself at the intersection of performance medicine and longevity optimization, targeting patients who want proactive hormonal and metabolic management rather than reactive disease treatment.

The Cash Concierge Structure

Cash concierge telehealth has expanded significantly since the DEA's 2023 interim rule on telemedicine prescribing of controlled substances, which clarified that practitioners may prescribe Schedule III medications (including testosterone) via telehealth when a valid patient-practitioner relationship exists and state law permits. The DEA's telemedicine framework and subsequent guidance from the Ryan Haight Online Pharmacy Consumer Protection Act govern these interactions.

Under this model, patients typically pay a membership or consultation fee, receive an at-home or local-lab blood draw, and then receive a care plan from a licensed physician. Medications are shipped through licensed compounding or retail pharmacies. This structure lets clinicians spend more time per patient than typical insurance-constrained visits allow, which matters for protocols like testosterone replacement therapy (TRT) that require serial lab monitoring.

Why Cash-Pay Exists in Hormone Medicine

Standard insurance plans frequently deny coverage for testosterone therapy in men with low-normal serum testosterone, even when symptoms are present. The American Urological Association's 2018 testosterone deficiency guideline defines hypogonadism by both biochemical and symptomatic criteria, noting that a morning total testosterone below 300 ng/dL combined with symptoms warrants a treatment discussion. Insurance denials at levels of 301 to 400 ng/dL are routine, pushing symptomatic patients toward cash-pay options. Cash concierge companies fill that gap by accepting patients whose labs fall in the gray zone but who carry a genuine clinical burden.

What Does 1st Optimal Prescribe?

1st Optimal's prescribing scope covers the major categories of performance and longevity medicine: testosterone replacement, GLP-1 receptor agonists, peptide therapies, thyroid optimization, and ancillary medications. Each category carries its own evidence base and regulatory status.

Testosterone Replacement Therapy (TRT)

TRT is the most evidence-supported offering in the performance-longevity telehealth space. A 2023 systematic review in the Journal of Clinical Endocrinology and Metabolism analyzed 58 randomized controlled trials and found that testosterone therapy in hypogonadal men significantly improved libido, erectile function, bone mineral density, and lean mass. The landmark TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase major adverse cardiovascular events (MACE) compared to placebo in men aged 45 to 80 with hypogonadism and elevated cardiovascular risk, with a hazard ratio of 0.96 (95% CI 0.78 to 1.17; P<0.001 for non-inferiority). That result substantially de-risked TRT for a patient population previously considered borderline.

Standard TRT protocols include weekly intramuscular or subcutaneous injections of testosterone cypionate (typically 100 to 200 mg per week), topical gels, or subcutaneous pellets. Monitoring involves serial measurement of total testosterone, free testosterone, hematocrit, PSA, and estradiol every 3 to 6 months per Endocrine Society guidelines.

GLP-1 Receptor Agonists

GLP-1 agonists, including semaglutide and tirzepatide, sit at the center of current metabolic medicine. In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, as published in the New England Journal of Medicine. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved 20.9% mean weight loss at 72 weeks versus 3.1% placebo, reported in the New England Journal of Medicine. Both drugs carry FDA approval for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity.

Compounded semaglutide from 503B outsourcing facilities was legally permissible during the FDA shortage period through 2024. The FDA removed semaglutide from its drug shortage list in February 2025, which means telehealth companies prescribing compounded semaglutide after that date operate in a legally and regulatorily changed environment. Patients should verify that any GLP-1 prescription they receive comes from an FDA-approved brand or a 503A/503B pharmacy with a valid shortage justification, per FDA compounding guidance.

Peptide Therapies

Peptide therapies represent the most regulatory-complex category in 1st Optimal's offering. Growth hormone secretagogues such as sermorelin and ipamorelin/CJC-1295 are not FDA-approved drugs and are not on the FDA's list of bulk drug substances permitted for compounding under 503A or 503B frameworks. The FDA placed BPC-157 and several other peptides on the Category 2 list of substances that raise safety concerns for compounding.

A 2019 meta-analysis in JAMA Internal Medicine reviewed growth hormone secretagogue trials and found modest improvements in lean mass but no significant benefit for strength or functional outcomes in healthy older adults, with the caveat that most trials were short and underpowered. Patients considering peptide protocols should ask their prescribing physician for the specific peptide name, its FDA regulatory category, the pharmacy's 503A or 503B licensure, and the supporting clinical evidence before proceeding.

Thyroid and Ancillary Protocols

Some performance longevity clinics, including those following similar models to 1st Optimal, offer optimization of thyroid function using combination T4/T3 therapy (levothyroxine plus liothyronine). The American Thyroid Association's 2014 guidelines, published in Thyroid, note that combination therapy may benefit a subset of patients who remain symptomatic on T4 monotherapy, but evidence from randomized trials has been inconsistent. Clinicians who prescribe T3 outside standard reference ranges take on responsibility for close monitoring of cardiac and bone endpoints.

How Does 1st Optimal Compare to Alternatives?

The cash concierge performance-longevity telehealth market includes several well-known platforms: Hone Health, Maximus, Fountain Life, Function Health, Marek Health, and Defy Medical, among others. Comparing them requires looking at three dimensions: clinical rigor, pricing, and prescribing scope.

Clinical Protocol Depth

Platforms vary substantially in how much diagnostic depth they offer at intake. Some limit intake labs to a basic hormone panel (total testosterone, LH, FSH, estradiol), while others order comprehensive metabolic, lipid, inflammatory, and genetic panels. More extensive baseline data generally supports more individualized prescribing. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends measuring total testosterone on at least two occasions before initiating therapy, along with LH, FSH, and prolactin to characterize the deficiency as primary or secondary. Platforms that skip this characterization miss clinically meaningful distinctions: secondary hypogonadism (low LH with low testosterone) may indicate a pituitary lesion requiring imaging before TRT is started.

Pricing Comparison

Cash concierge TRT programs typically range from approximately $99 per month on the low end (labs not always included) to $400 or more per month for comprehensive panels plus physician oversight. GLP-1 programs add significant cost: brand-name semaglutide (Ozempic or Wegovy) costs approximately $900 to $1,400 per month without insurance, while compounded alternatives historically ran $150 to $400 per month. Tirzepatide (Zepbound) carries a list price near $1,060 per month.

The table below offers a rough positioning framework for evaluating cash concierge platforms:

| Dimension | Budget Tier | Mid-Tier (1st Optimal range) | Premium Tier | |---|---|---|---| | Intake lab panel | Basic hormone panel only | Comprehensive metabolic + hormone | Full biomarker + genetic + imaging | | Physician access | Async messaging | Sync video + async | Dedicated physician with direct line | | Prescribing scope | TRT only | TRT + GLP-1 + select peptides | TRT + GLP-1 + peptides + advanced Dx | | Monthly cost range | $99 to $199 | $200 to $400 | $500+ | | Monitoring cadence | Annual or biannual labs | Quarterly labs | Continuous + quarterly labs |

Regulatory Compliance as a Differentiator

Any platform prescribing testosterone to men must comply with the DEA's Schedule III controlled substance regulations, including record-keeping, prescription validity, and patient identification requirements. DEA registration and compliance standards are not optional. Platforms that operate sloppy intake processes, skip confirmatory lab requirements, or ship medications before a valid prescription exists expose both patients and prescribers to legal risk. When evaluating any concierge telehealth company, patients should verify that the prescribing physician holds a DEA registration in the patient's state and that the dispensing pharmacy holds a valid state pharmacy license.

Is 1st Optimal Legit? Evaluating Clinical Credibility

Assessing the legitimacy of any telehealth company in this space requires a structured approach. Board certification of prescribing physicians, transparent lab-ordering policies, named pharmacies, and published protocols are markers of a serious clinical operation.

Physician Oversight and State Licensure

Legitimate telehealth companies in performance medicine employ or contract with physicians who hold board certification in relevant specialties, such as urology, endocrinology, internal medicine, or family medicine, and who hold DEA and state medical licenses in every state where they see patients. The Federation of State Medical Boards' model policy on telemedicine requires that a valid patient-physician relationship exist before any prescription is issued, defined by a history and physical (which may be performed via synchronous video) and review of objective data including laboratory results.

Lab-Guided Protocols as a Quality Signal

A company that prescribes testosterone or GLP-1 agents without requiring baseline labs before the first prescription is a red flag. The Endocrine Society's clinical practice guideline on testosterone therapy, available via PubMed, specifies that TRT should be initiated only after documentation of biochemical hypogonadism on two separate morning samples. Platforms that skip this step are not following evidence-based practice. Patients should request to see the lab requisition before their first consultation and confirm that monitoring labs are scheduled at 3 and 6 months after initiation.

What Patient Reviews Actually Signal

Online reviews of telehealth companies in this space tend to cluster around two themes: speed of onboarding and perceived improvement in symptoms. Neither is a reliable proxy for clinical quality. A practice that onboards quickly by skipping confirmatory labs or by using a rubber-stamp prescribing process may generate strong initial reviews before harms emerge. Symptom improvement without objective monitoring can mask rising hematocrit (a known risk of TRT) or worsening glycemic control. The FDA's MedWatch reporting system exists precisely because consumer reviews do not capture adverse events systematically. Patients should treat positive reviews as one signal among several, not as evidence of clinical rigor.

Performance and Longevity Medicine: Does the Evidence Support the Category?

Performance and longevity medicine as a clinical category spans a wide evidence spectrum. Some interventions are supported by large randomized trials; others rest on mechanistic rationale and small observational data.

Strong Evidence Tier

Testosterone replacement in biochemically confirmed hypogonadal men, GLP-1 agonists for obesity and type 2 diabetes, and thyroid replacement for overt hypothyroidism all carry Level 1 or Level 2 evidence from multiple large randomized controlled trials. The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes, establishing a cardiovascular indication beyond weight alone.

Moderate Evidence Tier

Combination T3/T4 thyroid therapy for euthyroid-symptomatic patients, human chorionic gonadotropin (hCG) co-administration with TRT to preserve testicular volume and fertility, and metformin for longevity (based on the TAME trial design described by NIH) sit in a moderate-evidence category: plausible mechanisms, some clinical trial support, but not yet standard-of-care.

Weak or Investigational Evidence Tier

Most peptide therapies, high-dose antioxidant regimens, and off-label growth hormone use for non-deficient patients sit in the weak or investigational tier. A Cochrane review on growth hormone for healthy adults found no clinically meaningful improvement in strength, exercise capacity, or quality of life, while identifying adverse effects including fluid retention, carpal tunnel syndrome, and glucose intolerance. Patients should ask their clinician to identify which evidence tier applies to each proposed intervention before agreeing to treatment.

Key Questions to Ask Any Concierge Performance Clinic

Before enrolling with 1st Optimal or any comparable platform, patients should get clear answers to the following:

• Does the prescribing physician hold a DEA registration and state medical license in my state?
• Are baseline labs required before any prescription is issued, and which lab values trigger treatment?
• Which pharmacy will dispense my medications, and is it a 503A or 503B facility for compounded drugs?
• What monitoring schedule applies after initiation, and what lab thresholds trigger dose changes or discontinuation?
• What is the protocol if I experience a potential adverse effect between scheduled visits?

The American Association of Clinical Endocrinology's clinical practice guidelines provide benchmarks for hormone management that patients can use to evaluate whether a proposed protocol meets professional standards.